Physician profile
Charles R Johnson
NPI 1992999122
$7,196.64
in general payments reported to CMS, 2019-2025
33 companies · $981 in 2025
The $981 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,275 · 2020: $1,031 · 2021: $929 · 2022: $902 · 2023: $1,334 · 2024: $745 · 2025: $981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,885 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,884.89 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $816.36 | 2019-2025 | Repatha, Prolia, Otezla |
| Astrazeneca Pharmaceuticals LP | $774.83 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $758.09 | 2021-2025 | |
| Novo Nordisk INC | $706.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $650.39 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $373.13 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $370.92 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $350.98 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $340.32 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $330.52 | 2019-2025 | |
| Amarin Pharma, INC. | $249.57 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $205.94 | 2019-2022 | |
| Mylan Specialty L.P. | $161.66 | 2019-2024 | Yupelri |
| Exact Sciences Corporation | $120.34 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $119.90 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $95.71 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $79.17 | 2019-2025 | Gardasil 9, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.73 | 2019-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $75.13 | 2022 | |
| Allergan, INC. | $74.68 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.92 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $54.50 | 2019-2025 | Eliquis, Camzyos |
| Almatica Pharma LLC | $50.44 | 2021 | |
| Abbott Laboratories | $43.17 | 2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Eisai INC. | $39.45 | 2020 | |
| Zyla Life Sciences, INC. | $38.67 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $37.38 | 2019 | |
| Optinose US, INC. | $29.30 | 2025 | |
| Verona Pharma, INC. | $27.44 | 2025 | Ohtuvayre |
| Idorsia Pharmaceuticals US INC | $23.60 | 2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $22.91 | 2021 | |
| Insmed, INC. | $21.54 | 2025 | Brinsupri |
| Astellas Pharma US INC | $13.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.